908 Devices (MASS) Competitors

$7.12 +0.14 (+2.01%)

Closing price 04:00 PM Eastern

Extended Trading

$7.11 -0.01 (-0.14%)

As of 04:10 PM Eastern

MASS vs. ALNT, EYPT, TRNS, FEIM, and CTKB

Should you buy 908 Devices stock or one of its competitors? MarketBeat compares 908 Devices with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 908 Devices include Allient (ALNT), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Frequency Electronics (FEIM), and Cytek Biosciences (CTKB). These companies are all part of the "measuring and control equipment" industry.

How does 908 Devices compare to Allient?

Allient (NASDAQ:ALNT) and 908 Devices (NASDAQ:MASS) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Allient and Allient both had 3 articles in the media. 908 Devices' average media sentiment score of 0.97 beat Allient's score of 0.27 indicating that 908 Devices is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allient	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
908 Devices	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allient has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, 908 Devices has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

61.6% of Allient shares are held by institutional investors. Comparatively, 88.1% of 908 Devices shares are held by institutional investors. 15.0% of Allient shares are held by insiders. Comparatively, 28.2% of 908 Devices shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Allient has higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allient	$554.48M	1.93	$22.03M	$1.43	43.94
908 Devices	$57.80M	4.66	$19.49M	-$1.00	N/A

Allient presently has a consensus target price of $72.25, suggesting a potential upside of 14.97%. 908 Devices has a consensus target price of $12.00, suggesting a potential upside of 68.54%. Given 908 Devices' higher probable upside, analysts plainly believe 908 Devices is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allient	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Allient has a net margin of 4.25% compared to 908 Devices' net margin of -62.40%. Allient's return on equity of 12.47% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allient	4.25%	12.47%	6.37%
908 Devices	-62.40%	-14.03%	-10.40%

Summary

Allient beats 908 Devices on 10 of the 15 factors compared between the two stocks.

How does 908 Devices compare to Eyepoint Pharmaceuticals?

908 Devices (NASDAQ:MASS) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

88.1% of 908 Devices shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 28.2% of 908 Devices shares are held by insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, 908 Devices had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for 908 Devices and 2 mentions for Eyepoint Pharmaceuticals. 908 Devices' average media sentiment score of 0.97 beat Eyepoint Pharmaceuticals' score of 0.10 indicating that 908 Devices is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

908 Devices has higher revenue and earnings than Eyepoint Pharmaceuticals. 908 Devices is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$57.80M	4.66	$19.49M	-$1.00	N/A
Eyepoint Pharmaceuticals	$31.37M	34.16	-$231.96M	-$3.50	N/A

908 Devices currently has a consensus target price of $12.00, indicating a potential upside of 68.54%. Eyepoint Pharmaceuticals has a consensus target price of $31.80, indicating a potential upside of 148.83%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

908 Devices has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

908 Devices has a net margin of -62.40% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. 908 Devices' return on equity of -14.03% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Summary

908 Devices beats Eyepoint Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does 908 Devices compare to Transcat?

908 Devices (NASDAQ:MASS) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

908 Devices presently has a consensus price target of $12.00, indicating a potential upside of 68.54%. Transcat has a consensus price target of $105.33, indicating a potential upside of 48.78%. Given 908 Devices' higher possible upside, analysts plainly believe 908 Devices is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

908 Devices has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, Transcat has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

908 Devices has higher earnings, but lower revenue than Transcat. 908 Devices is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$57.80M	4.66	$19.49M	-$1.00	N/A
Transcat	$278.42M	2.37	$14.52M	$0.85	83.29

Transcat has a net margin of 2.47% compared to 908 Devices' net margin of -62.40%. Transcat's return on equity of 6.15% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Transcat	2.47%	6.15%	4.15%

In the previous week, 908 Devices had 1 more articles in the media than Transcat. MarketBeat recorded 3 mentions for 908 Devices and 2 mentions for Transcat. 908 Devices' average media sentiment score of 0.97 beat Transcat's score of 0.00 indicating that 908 Devices is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.1% of 908 Devices shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 28.2% of 908 Devices shares are held by company insiders. Comparatively, 2.8% of Transcat shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Transcat beats 908 Devices on 11 of the 17 factors compared between the two stocks.

How does 908 Devices compare to Frequency Electronics?

908 Devices (NASDAQ:MASS) and Frequency Electronics (NASDAQ:FEIM) are both small-cap measuring and control equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

908 Devices has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Frequency Electronics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Frequency Electronics has higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$57.80M	4.66	$19.49M	-$1.00	N/A
Frequency Electronics	$69.81M	8.44	$23.69M	$0.75	79.85

In the previous week, Frequency Electronics had 1 more articles in the media than 908 Devices. MarketBeat recorded 4 mentions for Frequency Electronics and 3 mentions for 908 Devices. 908 Devices' average media sentiment score of 0.97 beat Frequency Electronics' score of 0.13 indicating that 908 Devices is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Frequency Electronics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Frequency Electronics has a net margin of 10.78% compared to 908 Devices' net margin of -62.40%. Frequency Electronics' return on equity of 12.69% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Frequency Electronics	10.78%	12.69%	7.84%

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by insiders. Comparatively, 28.0% of Frequency Electronics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

908 Devices currently has a consensus price target of $12.00, indicating a potential upside of 68.54%. Frequency Electronics has a consensus price target of $43.67, indicating a potential downside of 27.09%. Given 908 Devices' higher possible upside, equities research analysts plainly believe 908 Devices is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Frequency Electronics beats 908 Devices on 11 of the 16 factors compared between the two stocks.

How does 908 Devices compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Cytek Biosciences presently has a consensus price target of $5.69, suggesting a potential upside of 43.62%. 908 Devices has a consensus price target of $12.00, suggesting a potential upside of 68.54%. Given 908 Devices' higher possible upside, analysts clearly believe 908 Devices is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, 908 Devices had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for 908 Devices and 1 mentions for Cytek Biosciences. 908 Devices' average media sentiment score of 0.97 beat Cytek Biosciences' score of 0.00 indicating that 908 Devices is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
908 Devices	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has a net margin of -36.25% compared to 908 Devices' net margin of -62.40%. Cytek Biosciences' return on equity of -10.07% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
908 Devices	-62.40%	-14.03%	-10.40%

Cytek Biosciences has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, 908 Devices has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

908 Devices has lower revenue, but higher earnings than Cytek Biosciences. 908 Devices is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.54	-$66.54M	-$0.57	N/A
908 Devices	$57.80M	4.66	$19.49M	-$1.00	N/A

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 88.1% of 908 Devices shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by insiders. Comparatively, 28.2% of 908 Devices shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cytek Biosciences beats 908 Devices on 9 of the 16 factors compared between the two stocks.

Get 908 Devices News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MASS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MASS vs. The Competition

Export

Metric	908 Devices	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$269.24M	$6.97B	$6.34B	$12.28B
Dividend Yield	N/A	1.70%	2.80%	5.36%
P/E Ratio	-7.12	50.25	20.92	25.48
Price / Sales	4.66	72.25	521.15	73.33
Price / Cash	N/A	24.40	43.18	55.00
Price / Book	2.01	6.51	9.98	7.01
Net Income	$19.49M	$158.81M	$3.55B	$335.16M
7 Day Performance	-2.47%	2.29%	0.40%	-0.30%
1 Month Performance	-1.93%	-0.69%	-0.04%	1.14%
1 Year Performance	53.12%	2.12%	34.95%	34.69%

908 Devices Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MASS 908 Devices	1.9092 of 5 stars	$7.12 +2.0%	$12.00 +68.5%	+41.3%	$269.24M	$57.80M	N/A	60	Gap Down
ALNT Allient	3.8137 of 5 stars	$59.34 -2.6%	$72.25 +21.8%	+99.0%	$1.01B	$560.59M	41.53	2,478
EYPT Eyepoint Pharmaceuticals	2.7145 of 5 stars	$11.85 +1.2%	$31.80 +168.5%	+101.3%	$996.45M	$7.61M	N/A	120
TRNS Transcat	2.4103 of 5 stars	$68.75 -11.5%	$105.33 +53.2%	-28.1%	$641.44M	$278.42M	80.88	1,245	Positive News Upcoming Earnings
FEIM Frequency Electronics	1.4031 of 5 stars	$57.04 -1.3%	$43.67 -23.4%	+232.6%	$562.54M	$69.81M	76.23	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MASS) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

908 Devices (MASS) Competitors

MASS vs. ALNT, EYPT, TRNS, FEIM, and CTKB

How does 908 Devices compare to Allient?

Summary

How does 908 Devices compare to Eyepoint Pharmaceuticals?

Summary

How does 908 Devices compare to Transcat?

Summary

How does 908 Devices compare to Frequency Electronics?

Summary

How does 908 Devices compare to Cytek Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASS vs. The Competition

908 Devices Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

908 Devices (MASS) Competitors

MASS vs. ALNT, EYPT, TRNS, FEIM, and CTKB

How does 908 Devices compare to Allient?

Does the media favor ALNT or MASS?

Which has more risk and volatility, ALNT or MASS?

Do insiders and institutionals hold more shares of ALNT or MASS?

Which has stronger earnings and valuation, ALNT or MASS?

Do analysts prefer ALNT or MASS?

Is ALNT or MASS more profitable?

Summary

How does 908 Devices compare to Eyepoint Pharmaceuticals?

Do insiders & institutionals have more ownership in MASS or EYPT?

Does the media prefer MASS or EYPT?

Which has better earnings and valuation, MASS or EYPT?

Do analysts recommend MASS or EYPT?

Which has more volatility & risk, MASS or EYPT?

Is MASS or EYPT more profitable?

Summary

How does 908 Devices compare to Transcat?

Do analysts rate MASS or TRNS?

Which has more volatility and risk, MASS or TRNS?

Which has preferable valuation and earnings, MASS or TRNS?

Is MASS or TRNS more profitable?

Does the media refer more to MASS or TRNS?

Do institutionals and insiders have more ownership in MASS or TRNS?

Summary

How does 908 Devices compare to Frequency Electronics?

Which has more volatility and risk, MASS or FEIM?

Which has preferable earnings and valuation, MASS or FEIM?

Does the media prefer MASS or FEIM?

Is MASS or FEIM more profitable?

Do institutionals & insiders believe in MASS or FEIM?

Do analysts rate MASS or FEIM?

Summary

How does 908 Devices compare to Cytek Biosciences?

Do analysts rate CTKB or MASS?

Does the media prefer CTKB or MASS?

Is CTKB or MASS more profitable?

Which has more volatility & risk, CTKB or MASS?

Which has better valuation & earnings, CTKB or MASS?

Do institutionals and insiders hold more shares of CTKB or MASS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASS vs. The Competition

908 Devices Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools